Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Jul 29, 2011

Premium

Proteome Sciences has appointed Glenn Barney vice president of business development in North America.

Previously, Barney was VP of business development for NextGen Sciences. He has also held senior positions at Decision Biomarkers and PerkinElmer.


Dario Alessi has been appointed director of the Medical Research Council's Protein Phosphorylation Unit at the University of Dundee, a research group dedicated to the study of protein phosphorylation.

Alessi is currently deputy director of the unit as well as a professor of signal transduction in the College of Life Sciences at the University of Dundee. In 2005 he was awarded the EMBO Gold Medal, a research prize for life scientists under the age of 40, and was elected a fellow of the Royal Society in 2008.

Alessi will succeed the current director Philip Cohen, who will step down in April 2012.


BG Medicine has appointed former BioMérieux CEO Stephane Bancel to serve as chairman of its board of directors.

Bancel will replace Noubar Afeyan, a company founder and chairman of the board since the company's inception as well as CEO and managing partner of Flagship Ventures. Afeyan will continue to serve on the firm's board.

The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.